Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LENZ 
LENZ Therapeutics Inc (LENZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LENZ (1-star) is a SELL. SELL since 3 days. Simulated Profits (-1.91%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $53
1 Year Target Price $53
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.94% | Avg. Invested days 33 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.17B USD | Price to earnings Ratio - | 1Y Target Price 53 |
Price to earnings Ratio - | 1Y Target Price 53 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 16.54 - 50.40 | Updated Date 10/15/2025 |
52 Weeks Range 16.54 - 50.40 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -337.14% |
Management Effectiveness
Return on Assets (TTM) -18.44% | Return on Equity (TTM) -26.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1169719678 | Price to Sales(TTM) 234.9 |
Enterprise Value 1169719678 | Price to Sales(TTM) 234.9 | ||
Enterprise Value to Revenue 233.94 | Enterprise Value to EBITDA -7.99 | Shares Outstanding 30270730 | Shares Floating 13943882 |
Shares Outstanding 30270730 | Shares Floating 13943882 | ||
Percent Insiders 2.73 | Percent Institutions 99.59 |
Upturn AI SWOT
LENZ Therapeutics Inc
Company Overview
History and Background
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing innovative ophthalmic pharmaceutical products that improve vision and quality of life. They are specifically targeting presbyopia (age-related blurry near vision).
Core Business Areas
- Presbyopia Treatment Development: LENZ Therapeutics is focused on developing and commercializing a pharmaceutical therapy for the treatment of presbyopia using aceclidine and pilocarpine.
Leadership and Structure
Dr. Eef Schimmelpennink serves as President and CEO. The company has a board of directors and a management team focused on research, clinical development, and commercial strategy.
Top Products and Market Share
Key Offerings
- LNZ100 (Aceclidine + Pilocarpine): LNZ100 is LENZ Therapeutics' lead investigational product, a preservative-free, fixed-dose combination of aceclidine and pilocarpine being developed for the treatment of presbyopia. Phase 3 trials are underway. Market share is currently 0% as the product is not yet approved. Competitors include AbbVie (AGN) with Vuity and others developing presbyopia treatments.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is large and growing, with a significant unmet need for effective and convenient presbyopia treatments. Several companies are developing pharmaceutical options, creating a competitive landscape.
Positioning
LENZ Therapeutics is positioned as an innovator in the presbyopia treatment space, focusing on developing a novel, comfortable, and effective pharmaceutical option. Their focus is on a preservative-free option which would lead to less redness and discomfort, creating a competitive advantage.
Total Addressable Market (TAM)
The estimated TAM for presbyopia treatments is billions of dollars annually. LENZ Therapeutics is positioned to capture a significant share of this market if LNZ100 is approved and successfully commercialized.
Upturn SWOT Analysis
Strengths
- Novel formulation of existing drugs
- Potential for improved comfort and tolerability compared to existing treatments
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Single product focus creates high dependence on LNZ100
- Reliance on positive clinical trial results and regulatory approval
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Risk of competition from other emerging presbyopia treatments
Opportunities
- Successful Phase 3 clinical trial results
- Regulatory approval of LNZ100
- Partnerships with larger pharmaceutical companies for commercialization
- Expansion of product pipeline to address other ophthalmic conditions
Threats
- Failure to achieve positive clinical trial results
- Regulatory rejection of LNZ100
- Competition from existing and emerging presbyopia treatments
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- ABBV
Competitive Landscape
LENZ Therapeutics aims to compete with existing treatments like AbbVie's Vuity by offering a preservative-free and potentially more comfortable option. They also aim to offer an innovative solution by combining two active ingredients into one solution.
Growth Trajectory and Initiatives
Historical Growth: LENZ Therapeutics is pre-revenue. Historical "growth" is measured by the successful completion of milestones and advancement of its product pipeline.
Future Projections: Future growth is dependent on the successful development and commercialization of LNZ100. Analyst estimates are not available.
Recent Initiatives: Recent initiatives include ongoing Phase 3 clinical trials for LNZ100 and preparations for regulatory submissions.
Summary
LENZ Therapeutics is a promising early-stage company developing a novel treatment for presbyopia. Its success hinges on the outcome of its Phase 3 trials and subsequent regulatory approval of LNZ100. The company needs to carefully manage its cash burn and navigate the competitive landscape to capitalize on its potential market opportunity. Competition from established players like AbbVie could prove challenging.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LENZ Therapeutics Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2021-06-25 | President, CEO, Secretary & Director Mr. Evert B. Schimmelpennink | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.lenz-tx.com |
Full time employees - | Website https://www.lenz-tx.com | ||
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.